Br-J-I effectively inhibited Fn-induced tumor-promoting effect of CRC and inflammation by directly killing Fn, which has the potential to become a novel therapy for regulating intestinal bacterial dysbiosis and an adjunct therapy for CRC. The gene discussed is FN1; the disease is neoplasm.